Gur Roshwalb

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA.

Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.

aMoon Ventures Y Sh Ltd (aMoon Ventures) is an venture capital firm founded in 2016 by Marius Nacht and Dr. Yair Schindel. The firm is headquartered in Israel.